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Abstract
Background: Pancratistatin, a natural compound extracted from Hymenocallis littoralis, can selectively induce 
apoptosis in several cancer cell lines. In this ex vivo study, we evaluated the effect of pancratistatin on peripheral blood 
mononuclear cells obtained from 15 leukemia patients prior to clinical intervention of newly diagnosed patients, as 
well as others of different ages in relapse and at various disease progression states.
Results: Mononuclear cells from healthy volunteers and leukemia patients were exposed to 1 μM pancratistatin for up 
to 48 h. Irrespective of leukemia type, pancratistatin induced apoptosis in the leukemic samples, with minimal effects 
on non-cancerous peripheral blood mononuclear control cells.
Conclusion: Our results show that pancratistatin is an effective and selective anti-cancer agent with potential for 
advancement to clinical trials.
Background
Chemotherapy for acute myeloid leukemia, despite ear-
nest attempts, has not significantly changed in the last 30
years. Treatment continues to be based on the cytotoxic
chemotherapies of anthracyclines and cytarabine. The
natural compound, pancratistatin, extracted from the
Hymenocallis littoralis, has broad-range efficacy against
several cancer cell lines at 1 μM, with minimal effect on
non-cancerous cell lines of the same origin [1,2]. Pan-
cratistatin treatment causes phosphatidyl-serine flip-
ping, caspase-3 activation, generation of reactive oxygen
species (ROS), and loss of mitochondrial membrane
potential, which leads to apoptosis in cultured T-cell (Jur-
kat) leukemia cells [3]. Although pancratistatin is a non-
genotoxic drug, its target has not yet been elucidated
[3,4]. The efficacy of pancratistatin in inducing apoptosis
selectively in cultured (commercial) cancer cell lines is
well established, though its effect on leukemia cells
obtained from patients has not been tested. In this study,
clinical leukemia and non-cancerous peripheral blood
mononuclear cells (ncPBMCs) were treated with pan-
cratistatin to determine its selectivity and efficacy to
induce apoptosis ex vivo. Activity of pancratistatin was
compared to that of the widely used chemotherapeutic,
paclitaxel, against cancer cells. Peripheral blood samples
from patients with a diagnosis of acute myeloid leukemia
(AML; n = 11), acute lymphoid leukemia (ALL; n = 1),
chronic myelogenous leukemia (CML; n = 1), chronic
myelomonocytic leukemia (CMML; n = 1) and Mantle
cell lym phoma (n = 1) were obtained. T he majority of
samples were taken at diagnosis, that is, in chemo-näive
patients. Of the 15 patients, 5 did not go into remission
with induction chemotherapy. The median duration of
remission was 3 months. Our pre-clinical results demon-
strate that pancratistatin is effective against all types of
leukemia tested and does not induce apoptosis in non-
cancerous mononuclear cells.
Methods
Cell Culture
Human T-cell (Jurkat) leukemia cells were purchased
from ATCC and maintained in RPMI 1640 medium sup-
plemented with 10% fetal bovine serum and 10 μM gen-
tamycin in an incubator set at 37°C and 5% CO2 in air.
Peripheral blood was obtained from leukemia patients at
the Windsor Regional Cancer Center (WRCC, Windsor
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Regional Hospital REB #04-043 and 04-044) upon writ-
ten, informed consent and from healthy non-smoking
volunteers aged 25-50 y (University of Windsor REB #04-
147). Whole blood samples were collected in BD Vacu-
tainer™ Cell Preparation Tubes, and mononuclear cells
were separated by density gradient centrifugation. The
isolated cells were maintained in RPMI 1640 media sup-
plemented and maintained in the same way as the Jurkat
cultures. Cells were treated within 3 h of collection with 1
μM pancratistatin or 500 nM paclitaxel for up to 48 h.
Apoptosis Assays
Apoptotic cells were detected by microscopy with cell-
permeable Hoechst 33342 dye (Molecular Probes, Eugene
OR) or by flow cytometry with Annexin-V AlexaFluor488
(Sigma-Aldrich, Missisauga, ON) using established pro-
tocols [1]. Briefly, cells were treated with 1 μM pan-
cratistatin for either 24 or 48 h, or with 500 nM paclitaxel
for 24 h. For flow cytometry, cells were washed twice in
room temperature PBS, resuspended in Annexin-V bind-
ing buffer and incubated with AlexaFluor-488 (1:50) for
15 min. They were washed in calcium-binding buffer and
a minimum of 20,000 were analyzed on a Beckman
Coulter Cytomics FC500 flow cytometer. To achieve the
highest cell number per sample, propidium idodide was
not used in this study. For microscopy, 5 min incubation
with 10 μM Hoechst 33342 dye was added to the
Annexin-V binding step. Brightly stained, condensed
nuclei were visible with Hoechst dye, characteristic of
apoptotic cells, as is phosphatidylserine externalization
detected by Annexin-V binding. Images were captured on
a n  i n v e r t e d  f l u o r e s c e n c e  m i c r o s c o p e  ( L e i c a  D M  I R B ,
Germany). The percentage of apoptotic cells was calcu-
lated from a minimum of 5 fields with >100 cells/field.
Statistical analysis included the unpaired t-test, and two-
tailed p value; † represents p < 0.05 between means of
untreated and pancratistatin treated leukemia samples,
which was taken as statistically significant.
Results
Pancratistatin induces apoptosis in cultured leukemia cells
From previous experiments on the effects of pancratista-
tin on cultured Jurkat cells (T-cell leukemia), the majority
of cells were apoptotic after 24 h [3]. Pancratistatin rap-
idly induced apoptosis in >80% of Jurkat cells in the pres-
ent study, whereas paclitaxel induced cell death in ~25%
of cells, as determined by flow cytometry using Annexin-
V AlexaFluor488 (Figure 1A).
Pancratistatin induces apoptosis in clinical leukemia 
samples
Table 1 gives details of each patient's age, leukemia type
and percent blasts at diagnosis, alongside their response
to pancratistatin treatment ex vivo. Apoptosis percentage
values are corrected for the percentage of apoptosis
observed in untreated samples of the same patient. All
diagnoses are 1st  occurrence unless otherwise stated.
Patients were diagnosed in the clinic with: Acute Myeloid
Leukemia (AML), subtyped as M0 - M7 or MDS (myelo-
dysplastic syndrome); Acute Monocytic Leukemia
(AMoL); Acute Lymphoblastic Leukemia (ALL), sub-
typed as Burkitt's (L3); Chronic Myelogenous Leukemia
(CML); or Chronic Myelomonocytic Leukemia (CMML).
Response to chemotherapy administered in the clinic is
indicated as complete response (CR), partial response
(PR), no response (NR), relapsed or censored. Nine of the
15 samples showed an increase in apoptosis of 40%
greater than untreated PBMCs of the same patient after
exposure to pancratistatin, as determined by Hoechst
staining (Table 1). This result was confirmed by detection
of Annexin-V AlexaFluor488 binding by flow cytometry
(Figure 1B). Figure 2 shows the efficacy of pancratistatin
on both cultured leukemia (Jurkat) cells and patient-
obtained leukemia PBMCs as observed by Hoechst stain-
ing and Annexin-V binding.
Pancratistatin is non-toxic to non-cancerous PBMCs
To determine if the apoptosis-inducing effect of pan-
cratistatin is selective for cancer cells, PBMCs isolated
from blood samples from healthy volunteers (n = 8) were
treated with 1 μM pancratistatin for up to 48 h. Interest-
ingly, pancratistatin did not enhance apoptosis in these
cells as in leukemic PBMC isolates, as determined by flow
cytometry analysis using Annexin-V binding and nuclear
morphology after Hoechst staining (Figure 3A, B). The
cancer-selective apoptosis-inducing activity of pan-
cratistatin was a trend that was observed in all samples
obtained (Figure 4). This data demonstrates that pan-
cratistatin is selectively toxic to cancer cells ex vivo, irre-
spective of leukemia type, with an insignificant effect on
non-cancerous PBMC isolates.
Discussion
We report the novel finding that pancratistatin has selec-
tive apoptosis-inducing activity ex vivo at a low dose in a
random sampling (n = 15) of patient-obtained leukemias.
In contrast, pancratistatin has no effect on non-cancer-
ous peripheral blood mononuclear cells (n = 8). Cellular
subtypes in the PBMC samples may have differing sensi-
tivities to pancratistatin and separation of these popula-
tions is needed to clarify this point, but requires much
greater numbers. However, our results indicate that
PBMCs collected from healthy volunteers of various ages
were unaffected by pancratistatin. It is therefore unlikely
that pancratistatin is toxic to a particular subtype of non-
cancerous PBMC samples. The efficacy and selectivity of
pancratistatin against clinical leukemia is based on 2
characteristic features of apoptosis, viz. nuclear morphol-Griffin et al. Cancer Cell International 2010, 10:6
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ogy and lipid rearrangement within the plasma mem-
brane. Our results suggest that pancratistatin could be a
novel way to treat leukemia and may not cause adverse
effects common to intravenous chemotherapy [5]. Pacli-
taxel has been used to treat many types of cancer, includ-
ing leukemia, for over a decade; but it causes harsh side
effects often associated with chemotherapy [6]. In con-
trast, pancratistatin is more effective against cancer cells
than paclitaxel and has no significant effect on non-can-
cerous PBMC samples.
The mechanism of action and biochemical target of
pancratistatin is currently being studied. Due to its
broad-range effectiveness, we hypothesize that pan-
cratistatin may selectively target cancer cell mitochon-
dria, as opposed to a specific kinase or signalling protein.
We have previously shown that pancratistatin causes
mitochondrial membrane potential collapse and permea-
bilization, leading to reactive oxygen species (ROS) gen-
eration, cytochrome c leakage, caspase-3 activation, and
apoptosis [1,3,7]. Recent reports indicate that some leu-
kemia cells have increased basal levels of ROS, suggesting
increased susceptibility to oxidative stress, which can
lead to mitochondrial permeabilization and subsequent
apoptosis [8]. It has also been reported that cancer cell
mitochondria are dysfunctional and more susceptible to
attack compared to non-cancerous cell mitochondria,
which presents an opportunity for the development of
new chemotherapeutics, especially for leukemia [9]. Liu
et al. [10] reported that Lycorine, also an Amaryllidaceae
alkaloid, induces caspase-dependent apoptosis in leuke-
mia cells by down regulating the anti-apoptotic protein,
Mcl-1. It is possible that pancratistatin is also targeting a
protein that regulates the balance of apoptosis/survival,
which could explain the broad-range efficacy of this com-
pound against cancer cells in vitro. This is supported by
our evaluation of pancratistatin on patient-obtained leu-
kemia cells ex vivo at a low dose (1 μM).
Conclusions
Our results show that pancratistatin is an effective and
selective anti-cancer agent with potential for advance-
ment to clinical trials [11]. Targeted therapies are the holy
grail of systemic cancer therapy; the ideal drug should kill
cancer cells without harming non-cancerous cells. This is
an exciting development in the treatment of AML, for
which treatment regimens used over the last 30 years
have not significantly improved survival.
Figure 1 Detection of apoptosis in cells treated for 24 h with paclitaxel or pancratistatin. Flow cytometry with Annexin-V AlexaFluor 488 was 
used to detect apoptosis in Jurkat cells (A) and patient-obtained leukemic PBMCs (B) that were untreated, treated with 500 nM paclitaxel or treated 
with 1 μM pancratistatin for 24 h. The leukemic PBMCs were obtained from a chemo-näive female patient (65 y) diagnosed with AML -- M1. Flipping 
of phosphatidylserine from the inner to the outer leaflet of the plasma membrane, which binds to Annexin-V in the presence of calcium, is a charac-
teristic feature of apoptosis. A minimum of 20 000 events were measured for each sample on a Beckman Coulter Cytomics FC500 flow cytometer.Griffin et al. Cancer Cell International 2010, 10:6
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Figure 2 Response of clinical leukemia and cultured Jurkat cells to treatment with pancratistatin. The apoptotic effect of 24 h exposure to 1 
μM pancratistatin was observed by microscopy using cell-permeable Hoechst dye. Compared to the nuclear morphology of untreated cells (A, B), 
treatment with pancratistatin resulted in apoptosis characterized by condensed, brightly stained nuclei in Jurkat (E) and patient obtained leukemic 
PBMCs (F). Annexin-V binding, another characteristic feature of apoptosis, was minimal in untreated cells (C, D) in contrast to the binding observed 
after pancratistatin treatment (G, H). Hoechst and Annexin-V images are not of the same field.Griffin et al. Cancer Cell International 2010, 10:6
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Table 1: Clinical features, disease state, response in the clinic and in vitro of patient-obtained leukemia treated with 
pancratistatin.
Patient # Age Clinical 
Diagnosis
% Blasts Clinical 
Response
Exposure % Apoptosis
1 60 AML - M3 85% censored 24 h 64.9 ± 4.2
2 81 AML-M2 20% NR 24 h 33.5 ± 7.7
3 53 AMoL-M5a 96% CR 24 h 46.5 ± 7.9
4 73 CML 9% censored 24 h 63.9 ± 2.2
5 23 AML-M5a 70% NR 24 h 30.6 ± 1.6
6 66 ALL-L3 34% NR 48 h 61.8 ± 9.8
7 62 CMML-M4 32% NR 48 h 17.7 ± 2.7
8 74 AML-M2 60% NR 48 h 48.6 ± 6.7
9 45 AML 84% censored 48 h 63.9 ± 4.2
10 57 AML-M3 43% PR 48 h 70.8 ± 5.9
11 68 AML-M2 n/a CR 48 h 46.8 ± 12.2
12 80 Mantel cell 
lymphoma
0% censored 48 h 35.2 ± 6.6
13 47 AML 44% censored 48 h 37.3 ± 7.7
14 71 AML-M0, 
relapsed
52% relapsed 48 h 45.3 ± 11.3
15 65 AML-MDS, 
relapsed
48% CR 48 h 37.3 ± 8.5Griffin et al. Cancer Cell International 2010, 10:6
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Figure 3 Non-cancerous peripheral blood mono-nucleated cells (PBMCs) are relatively unaffected by pancratistatin. A) Flow cytometry anal-
ysis using Annexin-V AlexaFluor 488 was performed on PBMCs that were untreated or treated with 1 μM pancratistatin for 48 h. A minimum of 20 000 
events were measured for each sample on a Beckman Coulter Cytomics FC500 flow cytometer. B) Hoechst staining and Annexin-V binding depicts 
the selective activity of pancratistatin; there is minimal difference in nuclear morphology (i, ii) and amount of externalized phosphatidylserine (iii, iv) 
between untreated and treated non-cancerous PBMCs.Griffin et al. Cancer Cell International 2010, 10:6
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Figure 4 Comparative effect of 48 h treatment with pancratista-
tin. Leukemia samples (n = 10) and non-cancerous PBMCs (n = 8) treat-
ed for 48 h with pancratistatin were stained with Hoechst dye and 
counted manually (a minimum of 5 fields with 100 cells per field); per-
cent apoptosis was calculated per total cell number. Statistical analysis 
was performed (unpaired t-test, two-tailed p value); † represents p < 
0.05 between untreated and pancratistatin treated leukemia samples.